Kiora Pharmaceuticals (KPRX) Receivables - Accured (2015 - 2016)
Kiora Pharmaceuticals' (KPRX) quarterly Receivables - Accured came in at $89825.0 in Q4 2016, up 0.93% YoY from $88995.0 in Q1 2016, and little changed on a QoQ basis from $89616.0 in Q3 2016.
Kiora Pharmaceuticals (KPRX) Receivables - Accured (2015 - 2016) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 2 years of Receivables - Accured data on file, last reported at $89825.0 in Q4 2016.
- Quarterly Receivables - Accured rose 0.93% year-over-year to $89825.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $89825.0 (up 0.93% YoY) and the FY2016 annual result came in at $89825.0, up 0.93% from the prior year.
- Receivables - Accured steadied at $89825.0 in Q4 2016, from $89616.0 in the prior quarter.
- In the past five years, Receivables - Accured ranged from a high of $89825.0 in Q4 2016 to a low of $88995.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | - |
| 10 | Kiora Pharmaceuticals | 15.94 Mn | 15.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 89,825.00 |
| Dec 31, 2016 | 89,825.00 |
| Sep 30, 2016 | 89,616.00 |
| Sep 30, 2016 | 89,616.00 |
| Dec 31, 2015 | 88,995.00 |
| Dec 31, 2015 | 88,995.00 |